Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. - Wikidata - wikimedia - TriplyDB

Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.

Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.

http://www.wikidata.org/entity/Q44085580

about

Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer The safety of rofecoxib Nonsteroidal Anti-Inflammatory Drugs and the Kidney Water displacement leg volumetry in clinical studies--a discussion of error sources Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drugs: An Under-Recognized Public Health Issue.The cycloxygenase 2 (COX-2) story: it's time to explain, not inflame.Nephrotoxic potential of selective cyclooxygenase-2 inhibitors.Inhibition of the Prostaglandin Transporter PGT Lowers Blood Pressure in Hypertensive Rats and Mice Eicosanoids and tumor necrosis factor-alpha in the kidney.Economic analysis of strategies in the prevention of non-steroidal anti-inflammatory drug-induced complications in the gastrointestinal tract.Acute renal failure and interstitial nephritis in a patient treated with rofecoxib: case report and review of the literature.Prostaglandin E2 EP3 receptor regulates cyclooxygenase-2 expression in the kidney.Estimated GFR reporting is associated with decreased nonsteroidal anti-inflammatory drug prescribing and increased renal function Evaluation of the pharmacokinetics of digoxin in healthy subjects receiving etoricoxib Renal adverse effects of nonsteroidal anti-inflammatory drugs.How safe is Celecoxib for Asian-Indian patients with rheumatic diseases?Assessment of nonsteroidal anti-inflammatory drug-induced cardiotoxicity.Renal effects of prostaglandins and cyclooxygenase-2 inhibitors.Safety of carbonic anhydrase inhibitors.NFAT regulates calcium-sensing receptor-mediated TNF production.Efficacy and Safety of Celecoxib Therapy in Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials Cyclo-oxygenase-2 contributes to constitutive prostanoid production in rat kidney and brain.NSAIDs: the emperor's new dogma?On the selective inhibitors of Cyclooxygenase-2: do we have a last word?Celecoxib does not alter cardiovascular and renal function during dietary salt loading.Effect of nonsteroidal anti-inflammatory drugs with varying extent of COX-2-COX-1 selectivity on urinary sodium and potassium excretion in the rat.Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited.

P2860

Q28167125-C4D47A34-2DA1-4C32-8375-7E018C087D9A Q28176535-1FAD054B-F09D-410B-A5A9-9B4FBF9AD3EB Q28386844-8AEE599C-2878-447F-9630-254E7131FA97 Q30976670-E95FC6EE-F573-4A27-9878-085053C3D0A7 Q34556489-30CC6B7B-26D3-4DF7-891D-F9333064CC39 Q34636574-A92C76C7-0944-471F-900C-342B4C40E582 Q35675116-032809C5-96BA-4A2C-95AC-E11E14290F44 Q35677376-8DF64C1C-ADCC-4C42-AF9E-D560FD0AB80F Q35803739-67881CB4-A317-440D-B8E1-CD5473D98980 Q35845845-33CA6426-2E27-4B8C-A468-5976D28EE17E Q35873398-23853981-DB40-4DB1-9621-C40FBA576AD1 Q36208907-9108CAF5-0F72-4A6A-80C7-957BC9914DF0 Q36968784-919F9B1B-B5C4-4598-AA6C-0275D1B7258D Q37175779-DA0C8ED6-997D-48F0-8FD9-DC018FED68F1 Q37615395-658D6967-2C12-4192-8151-39E5E30AC83C Q38084689-C8A541C0-2D7F-4BC8-94BC-365E6925585C Q38161572-C03A17E7-5FDD-49F1-BE8F-8DD937C79783 Q38181481-3DC67951-0A11-47F5-8036-B2CCDB6D4F82 Q38194570-74CF21F5-3C4A-482B-B012-2833013508F7 Q38317275-5A1B0EE5-970A-425D-B70D-9E2C46CA295A Q38838396-8387537E-AD92-480E-8196-76F8402B1954 Q39499131-9FA1197F-F69F-4673-9CD3-3E4F72EFE2A8 Q41897798-80443F8B-B5B9-4235-9707-B619D3017D46 Q43678694-3BCE0E4A-2938-4721-B8EB-7742613609B3 Q45769050-F71220EB-0288-482B-AE95-D27C629A1751 Q46368581-49C779E9-E7EA-46E0-B18E-A2A4B96B99E0 Q47372560-21260FB3-183F-491D-B97C-83AA2DE26AD7

P2860

Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.

http://www.wikidata.org/entity/Q44085580

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Comparison of rofecoxib, celec ...... receiving a normal-salt diet.

@en

Comparison of rofecoxib, celec ...... receiving a normal-salt diet.

@nl

type

label

Comparison of rofecoxib, celec ...... receiving a normal-salt diet.

@en

Comparison of rofecoxib, celec ...... receiving a normal-salt diet.

@nl

prefLabel

Comparison of rofecoxib, celec ...... receiving a normal-salt diet.

@en

Comparison of rofecoxib, celec ...... receiving a normal-salt diet.

@nl

P1433

Q44085580-4768AA57-253D-4516-85B6-E08E9A5FC85B

P1476

Q44085580-E24778D0-5DE0-4745-B292-DD7D02D38D94

P2093

Q44085580-016BB92C-B6CA-42E4-B74C-6087CACAF5F3

Q44085580-1EAF23E1-1E52-45B0-BA23-90B547B5266B

Q44085580-22C4413D-52D8-4D35-BA5C-29B4261C4655

Q44085580-25E0BA4D-67E8-4193-ADCA-044C240400B9

Q44085580-6AB3046D-509E-482F-88F0-E62ADC7973A6

Q44085580-7D232F73-06C0-4487-BACC-62BBAC0D0609

Q44085580-AE81F7FC-E6F9-4AA1-8DEB-A2AAECB31CA6

Q44085580-BA2BA9B8-53BC-4AE9-AC87-7AD7911FE780

Q44085580-BDFD5B7D-E7BA-4BE9-A64F-F1411A0ED9EB

Q44085580-CAC81422-8255-4FC6-AB79-FE1C7694DFB3

P304

Q44085580-FB166D65-6047-4042-9A9E-791960331ED5

P31

Q44085580-4AC500E0-9482-4E57-B7CA-6EE41573B988

P356

Q44085580-199B129C-07A0-4B19-95D1-BD84CADB8A0B

P407

Q44085580-58744257-8E2C-4426-9923-6A915ACF67D8

P433

Q44085580-857C053B-3032-45A4-883D-4916EC14D9CE

P478

Q44085580-EA2D7C3D-A2DA-461D-894F-A54F1DB4E38B

P577

Q44085580-4BF6F63E-AC33-4AD4-BF74-C616D826EF48

P698

Q44085580-E8D8EA9A-3968-432E-8E07-CD149B7827F7

P356

MCP.2002.126182

P1433

Clinical Pharmacology & Therapeutics

P1476

Comparison of rofecoxib, celec ...... receiving a normal-salt diet.

@en

P2093

Brune K

http://www.w3.org/2001/XMLSchema#string

Gertz BJ

http://www.w3.org/2001/XMLSchema#string

Gottesdiener KM

http://www.w3.org/2001/XMLSchema#string

Holmes GB

http://www.w3.org/2001/XMLSchema#string

Kalyani RN

http://www.w3.org/2001/XMLSchema#string

Lasseter KC

http://www.w3.org/2001/XMLSchema#string

Laurenzi M

http://www.w3.org/2001/XMLSchema#string

Malice MP

http://www.w3.org/2001/XMLSchema#string

Redfern KJ

http://www.w3.org/2001/XMLSchema#string

Schwartz JI

http://www.w3.org/2001/XMLSchema#string

P304

50-61

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1067/MCP.2002.126182

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P577

2002-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12152004

http://www.w3.org/2001/XMLSchema#string